GET DAILY SIGNALSSight Sciences (SGHT) Delivers +25% Revenue Growth and Raises Full-Year Guidance
Key Takeaways
- Sight Sciences reported record total revenue of $24.9 million for the third quarter of 2026, up 25% year over year from $19.9 million.
- Interventional Glaucoma (IG) revenue grew 7% to $21.0 million, while Interventional Dry Eye (IDE) revenue hit a record $3.9 million, up 45% sequentially.
- Net loss narrowed to $6.8 million, or $0.12 per share, an improvement from $8.2 million, or $0.16 per share, a year earlier.
- Management raised full-year 2026 revenue guidance to $92 million–$93 million, up from the prior range of $88 million–$92 million.
- Cash usage fell sharply to $2.4 million in the quarter, down 74% year over year, strengthening the path toward cash-flow breakeven.
- For more on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Discover Trending AI Robots for AI-driven trading insights.
Why This Quarter Matters
Sight Sciences develops minimally invasive solutions for glaucoma and dry eye disease. The third-quarter 2026 results provide a useful test of whether the company can maintain double-digit revenue growth while narrowing losses and cutting cash burn. The quarter also included the commercial launch of the next-generation OMNI Ultra system and followed an FDA label expansion for TearCare, making this an important checkpoint on product momentum and the route to profitability.
Breaking Down the Q3 Numbers
Sight Sciences posted record revenue of $24.9 million for the third quarter ended September 30, 2026, a 25% increase from $19.9 million a year earlier. The figure topped consensus estimates of about $23.5 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Interventional Glaucoma revenue reached $21.0 million, up 7% year over year for a fifth straight quarter of growth. Interventional Dry Eye revenue climbed to a record $3.9 million, versus $0.2 million in the prior-year period and up 45% sequentially from $2.7 million in the second quarter.
Gross margin remained at 86%, unchanged from a year ago, while IDE gross margin improved to 79% from 38% on higher average selling prices. Total operating expenses rose 10% to $27.5 million.
The company reported a net loss of $6.8 million, or $0.12 per share, better than $8.2 million, or $0.16 per share, a year earlier. The loss per share matched consensus estimates.
Management lifted full-year 2026 revenue guidance to $92 million–$93 million, implying 19%–20% growth, from the previous $88 million–$92 million range. IG revenue is now expected at $80 million–$81 million and IDE revenue at roughly $12 million. Adjusted operating expense guidance stayed at $92 million–$94 million.
How Investors Are Reading the Results
Heading into the release, attention centered on whether Sight Sciences could extend double-digit growth while showing further progress toward cash-flow breakeven. The record revenue, 74% drop in cash usage, and raised full-year guidance addressed those points, pointing to a constructive outcome overall.
The IDE segment drew particular notice given its sequential acceleration and the FDA label expansion for TearCare. Management highlighted expanding payer coverage, including additional OMNI and SION coverage through Aetna that adds about 25 million covered lives. Ongoing net losses, the early stage of the dry eye opportunity, and competition in interventional glaucoma remain key risks investors are weighing.
What to Watch Going Forward
The main question now is whether Sight Sciences can convert revenue growth into a sustainable path to profitability without needing more equity financing. Management stated it remains positioned to reach cash-flow breakeven, and the sharp improvement in cash usage backs that view.
The full commercial launch of OMNI Ultra will be an important near-term catalyst. As the next version of the flagship glaucoma platform, surgeon adoption will be monitored closely as a signal of future IG growth. Early feedback has been positive, but upcoming quarters will show whether that translates into lasting utilization.
The IDE business is another key variable. With full-year IDE revenue now guided to about $12 million—well above $1.6 million in 2025—the pace of TearCare adoption and further payer decisions will matter. Management expects fee schedules and coverage policies to develop in coming quarters.
Operating expense discipline is also worth tracking. While adjusted operating expense guidance was unchanged, the company is investing to scale the IDE business. The balance between growth spending and narrowing losses will influence how the market views the margin outlook in future periods.
Using AI Tools in My Research
When evaluating companies like this, I regularly turn to Tickeron’s AI Screener to quickly filter for technical patterns, fundamentals, and performance metrics across the medical-device space. It helps surface comparable ideas efficiently and supports a more structured review of the broader sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for SGHT shows an upward move is likely
SGHT's Aroon Indicator triggered a bullish signal on October 08, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 126 similar instances where the Aroon Indicator showed a similar pattern. In 116 of the 126 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SGHT as a result. In 77 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for SGHT just turned positive on October 23, 2026. Looking at past instances where SGHT's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
SGHT moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where SGHT advanced for three days, in 212 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for SGHT moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 24 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SGHT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.082) is normal, around the industry mean (4.170). P/E Ratio (-17.600) is within average values for comparable stocks, (1.500). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (5.222) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SGHT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SGHT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
What Investment Choices Do I Have in My IRA?
What was the Best Day for the Markets?
Revolutionizing Fintech: The Potent Potential of Artificial Intelligence
How Do Short Positions Work? What is the Bearish Side of Trading.
How can one interpret Option Greeks? A Guide to the Four Corners of Risk Evaluation.
General Information
Industry MedicalNursingServices
Advertisement